EGFR and adenocarcinoma: Among patients with stage IV disease, treatment with erlotinib was associated with Hispanic and API heritages, not smoking, having an adenocarcinoma, having an EGFR mutation, living at least two months after cancer diagnosis and being treated at a larger hospital (Table 4).